A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) (VENICE I)

Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to evaluate the efficacy of venetoclax monotherapy in participants with relapsed/refractory CLL with or without the 17p deletion or TP53 mutation, including those who have received prior treatment with a B-cell receptor inhibitor.

Study Overview

• Status: Completed
• Conditions: Chronic Lymphocytic Leukemia
• Intervention / Treatment: Drug: Venetoclax

Detailed Description

Following the Screening period, all eligible participants initiate venetoclax on a once daily (QD) dosing schedule. To mitigate the risk for tumor lysis syndrome (TLS), dosing will start with a 5-week dose titration phase.

Participants may receive venetoclax for up to 2 years provided they continue to tolerate the drug, have no evidence of disease progression (based on investigator assessment), do not have unacceptable toxicity and do not meet any of the criteria for subject discontinuation. In countries where venetoclax is not commercially available, participants who continued to derive benefit after 2 years of treatment may extend their treatment for up to 2 additional years in an extended access phase. Participants in the extended access phase of this study who continue to derive benefit from venetoclax after the 2-year extension and are transferring to the venetoclax extension study, Study M19-388 (NCT03844048), may remain in Extended Access for up to 1 additional year or until the extension study is approved and initiated at the site, whichever is sooner.

• Study Type: Interventional
• Enrollment (Actual): 258
• Phase: Phase 3

Expanded Access

Available outside the clinical trial. See expanded access record.

Contacts and Locations

Study Locations

• Austria
  • Graz, Austria, 8036
    • LKH-Univ. Klinikum Graz /ID# 147547
  • Salzburg, Austria, 5020
    • LKH Salzburg and Paracelsus /ID# 147549
  • Wien, Austria, 1140
    • Hanusch Krankenhaus der WGKK /ID# 147548
• Belgium
  • Leuven, Belgium, 3000
    • UZ Leuven /ID# 147387
  • Bruxelles-Capitale
    • Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium, 1200
      • Cliniques Universitaires Saint Luc /ID# 147388
• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada, V5Z 1L3
      • BC Cancer Agency /ID# 153091
  • Nova Scotia
    • Halifax, Nova Scotia, Canada, B3H 1V7
      • Qe Ii Hsc /Id# 147460
  • Ontario
    • Hamilton, Ontario, Canada, L8V 1C3
      • Juravinski Cancer Clinic /ID# 149152
    • Toronto, Ontario, Canada, M4N 3M5
      • Sunnybrook Health Sciences Ctr /ID# 147462
  • Quebec
    • Quebec City, Quebec, Canada, G1R 2J6
      • CHU de Quebec-Universite Laval /ID# 150299
• Denmark
  • Hovedstaden
    • Herlev, Hovedstaden, Denmark, 2730
      • Herlev Hospital /ID# 150183
  • Midtjylland
    • Aarhus N, Midtjylland, Denmark, 8200
      • Aarhus University Hospital /ID# 147409
• Finland
  • Turku, Finland, 20520
    • Turku University Hospital /ID# 147551
• France
  • Bordeaux, France, 33076
    • Institut Bergonie /ID# 147482
  • Brest, France, 29200
    • CHRU de Brest - Hopital Morvan /ID# 147485
  • Strasbourg, France, 67085
    • clinique Sainte Anne /ID# 147556
  • Franche-Comte
    • Limoges CEDEX 1, Franche-Comte, France, 87042
      • CHU Dupuytren /ID# 147552
  • Poitou-Charentes
    • Poitiers, Poitou-Charentes, France, 86021
      • CHU de la miletrie /ID# 147484
• Germany
  • Berlin, Germany, 10707
    • Onkologische Schwerpunktpraxis /ID# 147516
  • Frankfurt, Germany, 60389
    • Cent fuer Haematologie und Onk /ID# 147511
  • Hamburg, Germany, 22081
    • OncoResearch Lerchenfeld GmbH /ID# 164044
  • Mannheim, Germany, 68161
    • Mannheimer Onkologiepraxis /ID# 147512
  • Munich, Germany, 80804
    • Staedt. Klinikum Schwabing /ID# 147510
• Greece
  • Thessaloniki, Greece, 57010
    • G. Papanikolaou Hospital /ID# 147518
  • Attiki
    • Athens, Attiki, Greece, 115 27
      • General Hospital of Athens Laiko /ID# 147517
• Ireland
  • Dublin, Ireland, D09 XR63
    • Beaumont Hospital /ID# 147522
  • Dublin
    • Dublin 8, Dublin, Ireland, D08 E9P6
      • St. James's Hospital /ID# 147519
• Israel
  • Nahariya, Israel, 22100
    • Galilee Medical Center /ID# 159971
  • Ramat Gan, Israel, 5262100
    • Sheba Medical Center /ID# 147509
  • Tel-Aviv
    • Tel Aviv-Yafo, Tel-Aviv, Israel, 6423906
      • Tel Aviv Sourasky Medical Ctr /ID# 151624
• Italy
  • Milan, Italy, 20132
    • Ospedale San Raffaele IRCCS /ID# 147504
  • Novara, Italy, 28100
    • AO Maggiore della Carita /ID# 147499
  • Emilia-Romagna
    • Bologna, Emilia-Romagna, Italy, 40138
      • A.O.U. Policlinico S.Orsola-Malpighi /ID# 147505
  • Lazio
    • Rome, Lazio, Italy, 00161
      • AP Romano Umberto I /ID# 147500
  • Lombardia
    • Milano, Lombardia, Italy, 20162
      • ASST Grande Ospedale Metropolitano Niguarda /ID# 147503
• Netherlands
  • Noord-Holland
    • Amsterdam, Noord-Holland, Netherlands, 1105 AZ
      • Academisch Medisch Centrum /ID# 147494
  • Zuid-Holland
    • Dordrecht, Zuid-Holland, Netherlands, 3318 AT
      • Albert Schweitzer Ziekenhuis /ID# 147495
• Norway
  • Oslo, Norway, 0450
    • Rikshospitalet OUS HF /ID# 201812
  • Hordaland
    • Bergen, Hordaland, Norway, 5021
      • Haukeland University Hospital /ID# 147382
• Portugal
  • Lisboa, Portugal, 1099-023
    • IPO Lisboa FG, EPE /ID# 147385
  • Porto, Portugal, 4200-072
    • IPO Porto FG, EPE /ID# 147389
• Puerto Rico
  • San Juan, Puerto Rico, 00959
    • Puerto Rico Hematology Oncolog /ID# 150003
• Spain
  • Barcelona, Spain, 08026
    • Hospital Santa Creu i Sant Pau /ID# 151230
  • Madrid, Spain, 28040
    • Fundacion Jimenez Diaz /ID# 151231
  • Majadahonda, Spain, 28222
    • Hosp Univ Puerta de Hierro /ID# 147391
  • Salamanca, Spain, 37007
    • Hospital Clinico Univ de Salamanca /ID# 147392
  • València, Spain, 46010
    • Hosp Clin Univ de Valencia /ID# 147396
• Sweden
  • Skane Lan
    • Lund, Skane Lan, Sweden, 222 41
      • Skanes Universitetssjukhus Lund /ID# 147439
  • Uppsala Lan
    • Uppsala, Uppsala Lan, Sweden, 751 85
      • Akademiska Sjukhuset /ID# 150184
• Switzerland
  • Bellinzona, Switzerland, 6501
    • Ospedale Regional Bellinzona e /ID# 151232
  • Geneve
    • Genève, Geneve, Switzerland, 1205
      • Hopitaux Universitaires de Geneve /ID# 147930
  • Zuerich
    • Zurich, Zuerich, Switzerland, 8006
      • University Hospital Zurich /ID# 157910
• Turkey
  • Ankara, Turkey, 6100
    • Ankara Univ Medical Faculty /ID# 147443
  • Istanbul, Turkey, 34093
    • Istanbul University Istanbul Medical Faculty /ID# 156040
  • Istanbul, Turkey, 34365
    • Vehbi Koc vakfi Amerikan Hasta /ID# 147325
  • Izmir, Turkey, 35340
    • Dokuz Eylul University /ID# 147442
  • Samsun, Turkey, 55139
    • Ondokuz mayis University Facul /ID# 147326
• United Kingdom
  • Blackpool, United Kingdom, FY3 8NR
    • Blackpool Teaching Hosp NHS /ID# 149581
  • Bristol, United Kingdom, BS2 8EG
    • Univ Hosp Bristol NHS Foundati /ID# 147647
  • Southampton, United Kingdom, SO16 6YD
    • Southampton General Hospital /ID# 147646
  • Wolverhampton, United Kingdom, WV10 0QP
    • The Royal Wolverhampton NHS Tr /ID# 147945
• United States
  • Kentucky
    • Louisville, Kentucky, United States, 40202-3700
      • Norton Cancer Institute /ID# 149788
  • Maryland
    • Baltimore, Maryland, United States, 21229
      • St. Agnes Cancer Center /ID# 149782
  • New Jersey
    • Hackensack, New Jersey, United States, 07601
      • Hackensack Univ Med Ctr /ID# 151574
  • Utah
    • Salt Lake City, Utah, United States, 84106
      • Utah Cancer Specialists /ID# 151604
  • Washington
    • Spokane, Washington, United States, 99202
      • Cancer Care Northwest /ID# 151605
  • West Virginia
    • Morgantown, West Virginia, United States, 26506
      • West Virginia Univ School Med /ID# 151602

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 99 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participant has Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2
• Participant has relapsed/refractory disease (received at least 1 prior therapy)

• Participant has diagnosis of CLL that meets published 2008 Modified International Workshop for Chronic Lymphocytic Leukemia National Cancer Institute Working Group (IWCLL NCI-WG) Guidelines and:

  • has an indication for treatment according to the 2008 Modified IWCLL NCI-WG criteria
  • has clinically measurable disease (lymphocytosis greater than 5 × 10^9/L and/or palpable and measurable nodes by physical exam and/or organomegaly assessed by physical exam)

• In addition, participants:

  • with or without 17p deletion or TP53 mutation, assessed by a local laboratory in bone marrow or peripheral blood are eligible
  • may have been previously treated with a prior B-cell receptor inhibitor
• Participant must have adequate bone marrow function, coagulation profile, renal, and hepatic function, per laboratory at Screening

Exclusion Criteria:

• Participant has developed Richter's transformation or Prolymphocytic leukemia
• Participant has previously received venetoclax

• History of active malignancies other than CLL within the past 2 years prior to first dose of venetoclax, with the exception of:

  • adequately treated in situ carcinoma of the cervix uteri
  • adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin
  • previous malignancy confined and surgically resected (or treated with other modalities) with curative intent
• Participant has active and uncontrolled autoimmune cytopenias (for 2 weeks prior to Screening), including autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura despite low dose corticosteroids
• Participant has undergone an allogeneic stem cell transplant

• Treatment with any of the following within five half-lives or 14 days (if half-life unknown) as applicable prior to the first dose of venetoclax, or clinically significant adverse effect(s)/toxicity(s) of the previous therapy have not resolved to < National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 Grade 2:

  • Any anti-cancer therapy including chemotherapy, or radiotherapy;
  • Investigational therapy, including targeted small molecule agents
• Participant is human immunodeficiency virus (HIV) positive
• Participant has known allergy to both xanthine oxidase inhibitors and rasburicase

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Venetoclax; Venetoclax will be administered orally once daily (QD) beginning with a dose-titration phase. The initial venetoclax dose is 20 mg QD. After 1 week of treatment at 20 mg QD, the dose will be escalated to 50 mg QD followed by subsequent increases, each after 1 week, to 100 mg QD, 200 mg QD and the maximum dose of 400 mg QD. Participants may continue to receive venetoclax for up to 2 years provided they continue to tolerate the drug, have no evidence of disease progression (based on investigator's assessment), do not have unacceptable toxicity, and do not meet any of the criteria for discontinuation. In countries where venetoclax is not commercially available, participants who continue to derive benefit after 2 years of treatment may be able to extend their treatment for up to 2 additional years, plus one additional year until the venetoclax extension study was open, determined on a case by case basis.

Drug: Venetoclax; Tablets for oral administration; Other Names: ABT-199; VENCLEXTA®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete Remission Rate in Participants Not Previously Treated With BCRi Therapy - Primary Analysis	Complete remission rate is defined as the percentage of participants achieving a best response of complete remission (CR) or complete remission with incomplete marrow recovery (CRi) assessed by the investigator based on 2008 Modified International Workshop for Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (IWCLL NCI-WG) criteria. CR required all of the following: Peripheral blood lymphocytes < 4000/μL; Absence of lymphadenopathy by physical examination and computed tomography scan; No hepatomegaly or splenomegaly by physical examination; Absence of disease or constitutional symptoms (unexplained fevers > 38°C, drenching night sweats, > 10% weight loss in last 6 months); Blood counts above the following:Neutrophils > 1500/μLPlatelets > 100,000/μLHemoglobin > 110 g/L; Bone marrow at least normocellular for age, < 30% lymphocytes. CRi was defined as for CR but with persistent cytopenia apparently unrelated to CLL but related to drug toxicity.	From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete Remission Rate in Participants Previously Treated With BCRi Therapy - Primary Analysis	Complete remission rate is defined as the percentage of participants achieving a best response of complete remission (CR) or complete remission with incomplete marrow recovery (CRi) assessed by the investigator based on 2008 modified IWCLL NCI-WG criteria. CR required all of the following: Peripheral blood lymphocytes < 4000/μL; Absence of lymphadenopathy by physical examination and computed tomography scan; No hepatomegaly or splenomegaly by physical examination; Absence of disease or constitutional symptoms (unexplained fevers > 38°C, drenching night sweats, > 10% weight loss in last 6 months); Blood counts above the following:Neutrophils > 1500/μLPlatelets > 100,000/μLHemoglobin > 110 g/L; Bone marrow at least normocellular for age, < 30% lymphocytes CRi was defined as for CR but with persistent cytopenia apparently unrelated to CLL but related to drug toxicity.	From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.
Overall Response Rate (ORR) - Primary Analysis	Overall response rate was defined as the percentage of participants with an overall best response of CR, CRi, nodular partial remission (nPR), or confirmed partial remission (PR) based on the 2008 modified IWCLL NCI-WG criteria assessed by the investigator. CR and CRi are defined above. nPR is defined as for CR but bone marrow nodules could be identified histologically. For PR at least 2 of the following must be met: 50% decrease in peripheral blood lymphocyte count from the Baseline value;; 50% reduction in lymphadenopathy;; 50% reduction in the size of the liver and/or spleen (if abnormal prior to therapy); In addition at least 1 of the following criteria must be met: Neutrophils > 1,500/μL or ≥ 50% improvement over Baseline;; Platelets > 100,000/μL or ≥ 50% improvement over Baseline;; Hemoglobin > 11.0 g/dL or ≥ 50% improvement over Baseline without transfusions or exogenous growth factors. PR must have been confirmed at least 7 weeks later.	From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.
Duration of Overall Response (DOR) - Primary Analysis	Duration of response was defined as the time from the date of first response (CR, CRi, nPR, or PR) to the earliest date that progressive disease (PD) was objectively documented (radiographic or clinical) or death. Duration of response was analyzed by Kaplan-Meier (K-M) methodology. If a participant was still responding the data were censored at the date of the last available disease assessment prior to the data cutoff date.	From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.
Time to Progression (TTP) - Primary Analysis	Time to progression was defined as the time from the date of first dose of venetoclax to the date of earliest PD (radiographic or clinical). Participants who did not experience disease progression were censored at the date of the last available disease assessment prior to the data cutoff date; participants with no post-baseline disease assessments were censored at the first dose date plus 1 day. Time to progression was estimated using Kaplan-Meier methodology.	From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.
Progression-Free Survival (PFS) - Primary Analysis	Progression-free survival (PFS) was defined as the time from the date of first dose of venetoclax to the date of earliest PD (radiographic or clinical) or death. Participants who did not experience disease progression or death were censored at the date of the last available disease assessment prior to the data cutoff date; participants with no post-baseline tumor assessment or clinical assessment for progression were censored at the date of first dose plus 1 day. Progression-free survival was analyzed by Kaplan-Meier methodology.	From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.
Overall Survival (OS) - Primary Analysis	Overall survival (time to death) was defined as the time from the first dose date of venetoclax to the date of death. If a participant had not died the data were censored at the date when they were last known to be alive prior to the cutoff date. Overall survival was analyzed using Kaplan-Meier methodology.	From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.
Change From Baseline in Functional Assessment of Cancer Therapy - Leukemia Questionnaire (FACT-Leu)	The FACT-Leu is a 44-item, leukemia-specific questionnaire designed to assess health-related quality of life (HRQoL) and leukemia-specific symptoms using a core set of questions (Functional Assessment of Cancer Therapy-General; FACT-G), and a cancer site-specific leukemia subscale. Questions are scored on a scale from 0 (not at all) to 4 (very much). FACT-G consists of 27 general items divided into 4 primary HRQoL domains: Physical Well-being (PWB; 7 items; score range 0-28), Social/Family Well-being (SWB; 7 items; score range 0-28), Emotional Well-being (EWB; 6 items; score range 0-24), Functional Well-being (FWB; 7 items; score range 0-28). The leukemia subscale consists of 17 items (score range 0-68) that assess patient concerns relating to leukemia. Three summary scales were calculated: FACT-Trial Outcome Index composed of the PWB, FWB, and leukemia subscale (score range 0-124); FACT-G (score range 0-108) and the FACT-Leu Total (range 0-176). Higher scores reflect better HRQoL.	Baseline and Weeks 48 and 108
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue)	The FACIT-Fatigue questionnaire measures fatigue and its effect on functioning and daily activities. The FACIT-Fatigue includes 13 items answered on a 5-point rating scale based on a 7-day recall period. Scores range from 0 to 52, with lower scores reflecting greater fatigue.	Baseline and Weeks 48 and 108
Change From Baseline in EuroQoL 5 Dimension 5 Level Questionnaire (EQ-5D-5L) Health Index Score	The EQ-5D-5L is a generic measure of health status consisting of two parts: a descriptive system consisting of 5 items and a visual analog scale (VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The participant is asked to rate each dimension on 5 levels of severity (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, 5: extreme problems). The scores for the 5 dimensions are used to compute a single health utility index score representing the general health status of the individual. The health index score ranges from zero (defined as a health state equivalent to being dead) to 1 (full health).	Baseline and Weeks 48 and 108
Change From Baseline in EuroQoL 5 Dimension 5 Level Questionnaire (EQ-5D-5L) Visual Analog Scale Score	The EQ-5D-5L is a generic measure of health status consisting of two parts, a descriptive system consisting of 5 items and a visual analog scale (VAS). The VAS assesses the participant's self-rated overall health on a scale from 0 (worst health imaginable) to 100 (best health imaginable).	Baseline and Weeks 48 and 108

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete Remission Rate in Participants Not Previously Treated With BCRi Therapy - Final Analysis	Complete remission rate is defined as the percentage of participants achieving a best response of complete remission (CR) or complete remission with incomplete marrow recovery (CRi) assessed by the investigator based on 2008 modified IWCLL NCI-WG criteria. CR required all of the following: Peripheral blood lymphocytes < 4000/μL; Absence of lymphadenopathy by physical examination and computed tomography scan; No hepatomegaly or splenomegaly by physical examination; Absence of disease or constitutional symptoms (unexplained fevers > 38°C, drenching night sweats, > 10% weight loss in last 6 months); Blood counts above the following:Neutrophils > 1500/μLPlatelets > 100,000/μLHemoglobin > 110 g/L; Bone marrow at least normocellular for age, < 30% lymphocytes. CRi was defined as for CR but with persistent cytopenia apparently unrelated to CLL but related to drug toxicity.	From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.
Complete Remission Rate in Participants Previously Treated With BCRi Therapy - Final Analysis	Complete remission rate is defined as the percentage of participants achieving a best response of complete remission (CR) or complete remission with incomplete marrow recovery (CRi) assessed by the investigator based on 2008 modified IWCLL NCI-WG criteria. CR required all of the following: Peripheral blood lymphocytes < 4000/μL; Absence of lymphadenopathy by physical examination and computed tomography scan; No hepatomegaly or splenomegaly by physical examination; Absence of disease or constitutional symptoms (unexplained fevers > 38°C, drenching night sweats, > 10% weight loss in last 6 months); Blood counts above the following:Neutrophils > 1500/μLPlatelets > 100,000/μLHemoglobin > 110 g/L; Bone marrow at least normocellular for age, < 30% lymphocytes CRi was defined as for CR but with persistent cytopenia apparently unrelated to CLL but related to drug toxicity.	From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.
Overall Response Rate (ORR) - Final Analysis	Overall response rate was defined as the percentage of participants with an overall best response of CR, CRi, nodular partial remission (nPR), or confirmed partial remission (PR) based on the 2008 modified IWCLL NCI-WG criteria assessed by the investigator. CR and CRi are defined above. nPR is defined as for CR but bone marrow nodules could be identified histologically. For PR at least 2 of the following must be met: 50% decrease in peripheral blood lymphocyte count from the Baseline value;; 50% reduction in lymphadenopathy;; 50% reduction in the size of the liver and/or spleen (if abnormal prior to therapy); In addition at least 1 of the following criteria must be met: Neutrophils > 1,500/μL or ≥ 50% improvement over Baseline;; Platelets > 100,000/μL or ≥ 50% improvement over Baseline;; Hemoglobin > 11.0 g/dL or ≥ 50% improvement over Baseline without transfusions or exogenous growth factors. PR must have been confirmed at least 7 weeks later.	From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.
Duration of Overall Response (DOR) - Final Analysis	Duration of response was defined as the time from the date of first response (CR, CRi, nPR, or PR) to the earliest date that progressive disease (PD) was objectively documented (radiographic or clinical) or death. Duration of response was analyzed by Kaplan-Meier (K-M) methodology. If a participant was still responding the data were censored at the date of the last available disease assessment prior to the data cutoff date.	From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.
Time to Progression (TTP) - Final Analysis	Time to progression was defined as the time from the date of first dose of venetoclax to the date of earliest PD (radiographic or clinical). Participants who did not experience disease progression were censored at the date of the last available disease assessment prior to the data cutoff date; participants with no post-baseline disease assessments were censored at the first dose date plus 1 day. Time to progression was estimated using Kaplan-Meier methodology.	From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.
Progression-Free Survival (PFS) - Final Analysis	Progression-free survival (PFS) was defined as the time from the date of first dose of venetoclax to the date of earliest PD (radiographic or clinical) or death. Participants who did not experience disease progression or death were censored at the date of the last available disease assessment prior to the data cutoff date; participants with no post-baseline tumor assessment or clinical assessment for progression were censored at the date of first dose plus 1 day. Progression-free survival was analyzed by Kaplan-Meier methodology.	From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.
Overall Survival (OS) - Final Analysis	Overall survival (time to death) was defined as the time from the first dose date of venetoclax to the date of death. If a participant had not died the data were censored at the date when they were last known to be alive prior to the cutoff date. Overall survival was analyzed using Kaplan-Meier methodology.	From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.
Minimal Residual Disease (MRD) Negativity Rate - Primary Analysis	The MRD negativity rate is defined as the percentage of participants who had MRD negative status with less than one CLL cell per 10,000 leukocytes (< 10-⁴) in peripheral blood and bone marrow. MRD was evaluated using next-generation sequencing. Per protocol, peripheral blood MRD assessments were to be collected from all participants at Week 24 and Week 48 and at the time the bone marrow assessment for confirmation of CR/CRi, and bone marrow (BM) MRD assessments were to be collected for participants undergoing a bone marrow procedure for confirmation of CR/CRi. Participants with no blood or BM MRD assessments were included in the calculation of MRD negativity rate as not having MRD negative status.	From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.
Minimal Residual Disease (MRD) Negativity Rate - Final Analysis	The MRD negativity rate is defined as the percentage of participants who had MRD negative status with less than one CLL cell per 10,000 leukocytes (< 10-⁴) in peripheral blood and bone marrow. MRD was evaluated using next-generation sequencing. Per protocol, peripheral blood MRD assessments were to be collected from all participants at Week 24 and Week 48 and at the time the bone marrow assessment for confirmation of CR/CRi, and bone marrow (BM) MRD assessments were to be collected for participants undergoing a bone marrow procedure for confirmation of CR/CRi. Participants with no blood or BM MRD assessments were included in the calculation of MRD negativity rate as not having MRD negative status.	From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.

Collaborators and Investigators

• Sponsor: AbbVie

Study record dates

Study Major Dates

• Study Start (Actual): June 22, 2016
• Primary Completion (Actual): April 10, 2019
• Study Completion (Actual): March 11, 2022

Study Registration Dates

• First Submitted: April 26, 2016
• First Submitted That Met QC Criteria: April 27, 2016
• First Posted (Estimate): April 29, 2016

Study Record Updates

• Last Update Posted (Estimate): April 10, 2023
• Last Update Submitted That Met QC Criteria: April 7, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: Relapsed; Refractory; Oncology; Chronic Lymphocytic Leukemia; 17p Deletion; TP53 Mutation; B-Cell receptor inhibitor
• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Leukemia, B-Cell; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Antineoplastic Agents; Venetoclax
• Other Study ID Numbers: M15-550; 2015-003667-11 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
• IPD Sharing Time Frame: For details on when studies are available for sharing, please refer to the link below.
• IPD Sharing Access Criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No